Novartis stock
Price history
+28.23% over the period1 year: from CHF 105.78 (November 17, 2025) to CHF 135.64 (November 16, 2026), +28.23%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | CHF 135.64 |
| October 30, 2026 | CHF 133.78 |
| September 30, 2026 | CHF 119.96 |
| August 31, 2026 | CHF 123.26 |
| July 31, 2026 | CHF 126.60 |
| June 30, 2026 | CHF 126.58 |
| May 29, 2026 | CHF 117.82 |
| April 30, 2026 | CHF 115.90 |
| March 31, 2026 | CHF 120.86 |
| February 27, 2026 | CHF 130.50 |
| January 30, 2026 | CHF 114.62 |
| December 30, 2025 | CHF 109.60 |
| November 28, 2025 | CHF 104.48 |
| November 17, 2025 | CHF 105.78 |
At a glance
The company
Researches, develops, manufactures and sells pharmaceutical medicines in Switzerland and internationally
Latest results
Quarter to September 30, 2026 · EPS $2.46 (estimate $2.28)
TickerLandia's take on Novartis
- Pricier than similar companies: trailing 12-month P/E 32 vs 21 (+50%) in a group of 10.
- Strong point: Dividend (68/100 in its group). Weak point: Growth (32/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
+0.31% from the 52-week high
Analysts · 23 analysts
Average targetCHF 129.21−4.74% vs. price
Buy 8 · Hold 11 · Sell 4 · Hold
TickerLandia Fingerprint: Novartis
Compared with similar companies: high dividend, low growth, and high profitability.
Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricehigh62
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 32.1 72 Forward P/E 16.2 48 EV/EBITDA 12.2 54 Price/book 8.25 73 Price/sales 4.41 62 Profitabilityhigh65
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 75.2% 74 Net margin 17.5% 58 ROE 24.3% 60 ROA 10.9% 66 Operating margin 34.0% 66 Earnings stabilitylow38
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 5.6% 22 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 54 Growthlow32
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +4.70% 24 Earnings growth (year over year) −68.80% 10 Average revenue growth (3 years) +9.25% 62 Financial strengthlow36
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 0.82 62 Interest coverage 16.6 46 Current ratio 0.88 14 Debt/equitycounts in reverse: lower means more financial strength 1.29 23 Dividendhigh68
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 2.8% 65 Consecutive dividend years 30 years 62 Payout ratio 88.7% 77 Market momentumstrong65
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +3.81% 63 Relative strength (6 months) +0.39% 58 1-year return +26.78% 71 Distance from 200-day average +9.58% 67 Riskaverage56
How much the price swings.
Metric Value Position in group Volatility (60 days) 33.3% 70 Beta (1 year) 1.19 83 Maximum drawdown (12 months) 15.0% 15
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Novartis is pricier than similar companies
Novartis's P/E (trailing 12 months): 32.1, +50% against the median of a group of 10 similar companies (21.5).
Compared with 10 similar companies
| Metric | Novartis | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 32.1 | High | |
| Forward P/E | 16.2 | High | |
| Operating margin | 34.0% | High | |
| ROE | 24.3% | Middle | |
| Debt/equity | 1.29 | High |
Grey band: the middle half of the group; tick: the median; dot: Novartis. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$15.03B
Latest quarter · Q3 2026
Net income
$1.2B
Latest quarter · Q3 2026
Quarterly net margin
8.0%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- CHF 253.19B
- P/E
- 32.1
- EPS
- CHF 4.17
- Volume
- 3.38M
- Daily trading
- €500.59M
- Dividend yield
- 2.73%
- Last ex-dividend on March 10, 2026
How Novartis is changing
All resultsRevenue grew 2.6% a year on average over the last 5 years
Operating margin rose from 21.2% to 33.5%
Profits turn into cash: free cash flow equal to 116% of net income
Returns
Novartis returns with dividends
CHF 1,000 invested in Novartis 5 years ago, on November 16, 2021, would be worth CHF 2,385 today with dividends reinvested: +138.49% in total, +18.99% per year. On price alone it would be CHF 1,871 (+87.07%).
| Period | Novartis | SMI | CHF 1,000 becomes |
|---|---|---|---|
| 1 month | +8.77% | +8.46% | CHF 1,088 |
| 6 months | +16.25% | +14.27% | CHF 1,162 |
| Year to date | +23.76% | +13.86% | CHF 1,238 |
| 1 year | +32.12% | +19.91% | CHF 1,321 |
| 3 years | +80.60% | +41.93% | CHF 1,806 |
| 5 years | +138.49% | +20.30% | CHF 2,385 |
| 10 years | +249.14% | +90.88% | CHF 3,491 |
Over the last 6 months it has done better than 28% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. SMI: price only. Calculate your investment
The chart in detail
Novartis: technical analysis
Novartis is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is at its all-time closing high.
- Trend
- Upward
- RSI (14 sessions)
- 68
- Between 30 and 70
- vs 200-session average
- +10.78%
Active signals
New 52-week high.
Close above the high of the previous 55 sessions.
Support and resistance
Price areas where Novartis has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last priceCHF 135.64
- SupportCHF 130.87−3.52%3 touches, last on November 6, 2026
- SupportCHF 128.29−5.42%2 touches, last on August 11, 2026
- SupportCHF 123.06−9.27%5 touches, last on September 30, 2026
Volatility and risk
Over the last year it has moved roughly in line with the SMI.
- Beta (1 year) vs SMI
- 1.19
- Volatility (60 sessions, annualised)
- 33.3%
- Largest fall in the last year
- −14.97%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Novartis: seasonality
Average monthly price change over 32 years
Over the last 32 years, the strongest month for Novartis has been November: +1.89% on average, positive in 19 years out of 31. The weakest has been January: −0.83% on average, positive in 12 years out of 31.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −0.83% | −0.52% | 12 of 31 |
| February | +0.86% | +0.57% | 18 of 31 |
| March | +0.66% | +0.50% | 17 of 31 |
| April | +1.27% | +1.73% | 20 of 31 |
| May | +0.64% | +0.87% | 19 of 32 |
| June | +1.70% | +1.09% | 22 of 32 |
| July | +0.63% | +0.10% | 17 of 32 |
| August | −0.38% | −0.58% | 16 of 32 |
| September | +1.14% | +1.69% | 19 of 32 |
| October | +0.20% | −0.68% | 13 of 32 |
| November | +1.89% | +2.43% | 19 of 31 |
| December | +0.67% | +0.57% | 18 of 31 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Novartis and its competitors
With 75,267 employees, the Swiss pharmaceutical group researches, develops, manufactures and sells prescription medicines in Switzerland and across the world. Its portfolio includes Entresto for chronic heart failure, Cosentyx for psoriasis and spondylitis, Kisqali, an oral kinase inhibitor, Pluvicto for advanced prostate cancer and Zolgensma for spinal muscular atrophy. Leqvio, which lowers LDL cholesterol, is developed under a license and collaboration agreement with Alnylam Pharmaceuticals. Its research and sales focus on heart and kidney disease, metabolic conditions, immunology, neuroscience, oncology and hematology.
- Headquarters
- Basel, Switzerland
- Employees
- 75,267
- Founded
- 1996
- Chief executive
- Vasant Narasimhan
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| NovartisNOVN | $301.99B | 34.0% | 32.1 | +16.25% |
| AstraZenecaAZN | $286.82B | 25.8% | 26.5 | +2.92% |
| Roche HoldingROP | $384.6B | 33.1% | 26.4 | +26.27% |
| Novo NordiskNOVO.B | $181.48B | 50.8% | 10.9 | −3.84% |
| SanofiSAN | $116.24B | 22.3% | 25.3 | +18.71% |
| GSKGSK | $101.36B | 30.5% | 17.9 | +3.57% |
Same industry or related industries, similar size. Compare Novartis with its competitors · Full profile
